Jounce Therapeutics Profile

8.37
USD 0.35  4.36%
100%
75%

Sale by Richard Murray of 12100 shares of Jounce Therapeutics

Jounce Therapeutics insider trading alert for sale of common stock by Richard Murray, CEO and President, on July 10, 2018. This event was filed by Jounce Therapeutics Inc with SEC on 2018-03-07. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Jounce Therapeutics Summary

Jounce Therapeutics (JNCE) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 112 people. Jounce Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 271.89 M. Jounce Therapeutics conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 32.48 M outstanding shares of which 4.17 M shares are currently shorted by private and institutional investors with about 8.77 trading days to cover. The company currently holds about 237.18 M in cash with (94.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.31.
Check Jounce Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 8.37HorizonTargetOdds Above 8.37
98.78%30 days 8.37 1.20%
Based on normal probability distribution, the odds of Jounce Therapeutics to move above current price in 30 days from now is about 1.2% (This Jounce Therapeutics probability density function shows the probability of Jounce Therapeutics Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Trv Gp Ii LlcCommon Shares10.2 M78.4 M
Trv Gp Iii LlcCommon Shares3 M23.4 M
View Jounce Therapeutics Diagnostics

Selected Jounce Therapeutics Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Risk Adjusted
Performance Score (0 to 100)
3 
Chance of
Financial Distress (0 to 100%)
49 
Equity ratings for Jounce Therapeutics are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. Jounce Therapeutics operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 112 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Jounce Therapeutics SEC Filings
Jounce Therapeutics SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameJounce Therapeutics
President CEO, DirectorRichard MurrayView All
Thematic Classification
Currently Active Investing Idea
  Cancer Fighters
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationMASSACHUSETTS U.S.A
Business Address780 Memorial Drive
ExchangeBATS Exchange
CIK Number0001640455
CUSIP481116101
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.jouncetx.com
Phone857 259 3840
CurrencyUSD - US Dollar

Directors

Jounce Therapeutics Corporate Directors
Barbara Duncan Independent Director
Luis Diaz Director
Robert Kamen Independent Director
Please also check Risk vs Return Analysis. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.